These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 9030353)

  • 1. The correlation of Ki-67 staining indices with tumour doubling times in regrowing non-functioning pituitary adenomas.
    Ekramullah SM; Saitoh Y; Arita N; Ohnishi T; Hayakawa T
    Acta Neurochir (Wien); 1996; 138(12):1449-55. PubMed ID: 9030353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
    Saeger W; Lüdecke B; Lüdecke DK
    Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTTG and Ki-67 expression in pituitary adenomas.
    Wierzbicka-Tutka I; Sokołowski G; Bałdys-Waligórska A; Adamek D; Radwańska E; Gołkowski F
    Przegl Lek; 2016; 73(2):53-8. PubMed ID: 27197423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the growth rate and cavernous sinus invasion of pituitary adenomas.
    Kawamoto H; Uozumi T; Kawamoto K; Arita K; Yano T; Hirohata T
    Acta Neurochir (Wien); 1995; 136(1-2):37-43. PubMed ID: 8748825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of proliferation indices in human anterior pituitary adenomas using formalin-fixed tissue and in vitro cell culture.
    Atkin SL; Green VL; Hipkin LJ; Landolt AM; Foy PM; Jeffreys RV; White MC
    J Neurosurg; 1997 Jul; 87(1):85-8. PubMed ID: 9202270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas.
    Mastronardi L; Guiducci A; Puzzilli F
    BMC Cancer; 2001; 1():12. PubMed ID: 11570981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of Ki-67 labeling index in pituitary adenomas using MIB-1 monoclonal antibody.
    Lath R; Chacko G; Chandy MJ
    Neurol India; 2001 Jun; 49(2):144-7. PubMed ID: 11447433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables.
    Matsuyama J
    Neurol Med Chir (Tokyo); 2012; 52(8):563-9. PubMed ID: 22976139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features and growth fractions of pituitary adenomas.
    Yonezawa K; Tamaki N; Kokunai T
    Surg Neurol; 1997 Nov; 48(5):494-500. PubMed ID: 9352815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Non-functioning pituitary adenomas: clinical features and immunohistochemistry].
    Ferreira JE; de Mello PA; de Magalhães AV; Botelho CH; Naves LA; Nosé V; Schmitt F
    Arq Neuropsiquiatr; 2005 Dec; 63(4):1070-8. PubMed ID: 16400431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proliferation markers in different types of clinically non-secreting pituitary adenomas.
    Schreiber S; Saeger W; Lüdecke DK
    Pituitary; 1999 May; 1(3-4):213-20. PubMed ID: 11081200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review.
    de Aguiar PH; Aires R; Laws ER; Isolan GR; Logullo A; Patil C; Katznelson L
    Neurol Res; 2010 Dec; 32(10):1060-71. PubMed ID: 20483025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunohistochemistry for pituitary hormones and Ki-67 in growth hormone producing pituitary adenomas].
    Brito J; Sáez L; Lemp M; Liberman C; Michelsen H; Araya AV
    Rev Med Chil; 2008 Jul; 136(7):831-6. PubMed ID: 18949157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The relationship between cell proliferation activity and secretory activity in pituitary adenoma--a review of 63 cases].
    Asano K; Kubo O; Tajika Y; Huang MC; Takakura K
    No To Shinkei; 1996 Jun; 48(6):543-9. PubMed ID: 8703557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas.
    Hentschel SJ; McCutcheon lE; Moore W; Durity FA
    Can J Neurol Sci; 2003 Aug; 30(3):215-9. PubMed ID: 12945944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time, patient age, and MIB-1 index.
    Tanaka Y; Hongo K; Tada T; Sakai K; Kakizawa Y; Kobayashi S
    J Neurosurg; 2003 Feb; 98(2):359-65. PubMed ID: 12593623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonfunctioning pituitary adenomas: association of Ki-67 and HMGA-1 labeling indices with residual tumor growth.
    Šteňo A; Bocko J; Rychlý B; Chorváth M; Celec P; Fabian M; Belan V; Šteňo J
    Acta Neurochir (Wien); 2014 Mar; 156(3):451-61; discussion 461. PubMed ID: 24452592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mdm2 and the p53 pathway in human pituitary adenomas.
    Suliman M; Royds J; Cullen D; Timperley W; Powell T; Battersby R; Jones TH
    Clin Endocrinol (Oxf); 2001 Mar; 54(3):317-25. PubMed ID: 11298083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms.
    Goldblum JR; Shannon R; Kaldjian EP; Thiny M; Davenport R; Thompson N; Lloyd RV
    Mod Pathol; 1993 Nov; 6(6):663-8. PubMed ID: 7508113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical evaluation of Ki-67, PCNA and MCM2 proteins proliferation index (PI) in advanced gastric cancer.
    Czyzewska J; Guzińska-Ustymowicz K; Pryczynicz A; Kemona A; Bandurski R
    Folia Histochem Cytobiol; 2009; 47(2):289-96. PubMed ID: 19995716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.